bsm-52225R [Primary Antibody]
Smad4 (3A1) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Smad4

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 4089

Swiss Prot: Q13485

Source: Recombinant human Smad4 protein, around N-terminal 1-200aa.

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.

Storage: Store at -20°C for 12 months..

Background:

In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

Size: 100ul

Concentration: 1ug/ul

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: PC-12 lysates probed with Smad4 (3A1) Monoclonal Antibody (bsm-52225R) at 1:1000 overnight at 4˚C. Followed by a conjugated secondary antibody.


Hela cells were stained with Smad4 (3A1) Monoclonal Antibody (bsm-52225R) at [1:200] incubated overnight at 4C followed by secondary antibody incubation, DAPI staining of the nuclei and detection.


Paraformaldehyde-fixed, paraffin embedded mouse brain; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer at 37°C for 20min; Antibody incubation with Smad4 (3A1) Monoclonal Antibody, (bsm-52225R) at 1:50 overnight at 4°C, followed by a conjugated secondary and DAB staining.


Lane 1: Lung lysates probed with Smad4 (3A1) Monoclonal Antibody, Unconjugated (bsm-52225R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Hela cell lysates; Lane 2: Jurkat cell lysates; Lane 3: HepG2 cell lysates; Lane 4: HL60 cell lysates ; Lane 5:Mouse Cerebrum lysates probed with Smad4 Monoclonal Antibody, Unconjugated (bsm-52225R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Human Hela cell lysates; Lane 2: Human Jurkat cell lysates; Lane 3:Human HepG2 cell lysates; Lane 4: Human HL-60 cell lysates; Lane 5: Mouse Cerebrum lysates probed with Smad4 monoclonal Antibody, Unconjugated (bsm-52225R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.